SCHEMBL19262183

SCHEMBL19262183

CC[C@H]1CC[C@](O)(c2ccc(F)cc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C19 P33261 1/20 0.41
OPRM1 P35372 2/20 0.41
OPRD1 P41143 2/20 0.41
OPRK1 P41145 2/20 0.41
OPRL1 P41146 2/20 0.41
DRD2 P14416 8/20 0.40
DRD4 P21917 2/20 0.40
DRD3 P35462 2/20 0.40
POLB P06746 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
SLC6A2 P23975 2/20 0.39
CHRNA1 P02708 1/20 0.39
CHRNG P07510 1/20 0.39
CHRNB1 P11230 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNB4 P30926 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11364231 0.83 OPRM1 (0.41) ALDH1A1CYP1A2CYP3A4OPRM1OPRD1
SCHEMBL12844042 0.82 OPRL1 (0.49) ALDH1A1OPRM1OPRD1OPRK1OPRL1
SCHEMBL25740959 0.82 OPRL1 (0.49) ALDH1A1OPRM1OPRD1OPRK1OPRL1
SCHEMBL19262091 0.82 SLC6A3 (0.43) OPRM1OPRD1OPRK1OPRL1DRD2
SCHEMBL18019019 0.80 CHRNA1 (0.45) LMNAALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL9542156 0.80 CHRNA1 (0.45) LMNAALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL10606317 0.79 OPRM1 (0.43) LMNAALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL10606314 0.79 OPRM1 (0.43) LMNAALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL11796702 0.78 OPRM1 (0.45) LMNAALDH1A1CYP1A2CYP3A4CYP2C19
SCHEMBL16591193 0.78 OPRM1 (0.45) LMNAALDH1A1CYP1A2CYP3A4CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9738642-B2 Triazolopyridine ether derivatives and their use in neurological and pyschiatric disorders BRISTOL-MYERS SQUIBB COMPANY (US) 2017-08-22 US disclosed